Peer-reviewed research and regulatory documents our medical team consults when evaluating intake for this protocol.
U.S. Food and Drug Administration (Federal Register)
Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
FDA confirmed the branded sermorelin product GEREF (originally approved under NDA 19-863 in 1990 and NDA 20-443 in 1997) was discontinued in 2008 for business reasons and not for any safety or effectiveness concern.
U.S. Food and Drug Administration — Federal Register, Vol. 78, No. 42, pp. 14095-14096 (Document 2013-04827) 2013
View source
U.S. Government Publishing Office (GovInfo)
Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness - GovInfo Granule Metadata
Official government archive metadata mirror confirming the FDA Federal Register notice on GEREF (sermorelin acetate) historical NDA approvals and non-safety withdrawal.
U.S. Food and Drug Administration — Federal Register, 78 FR 14095 2013
View source
Journal of Clinical Endocrinology & Metabolism (Oxford Academic)
Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy
Multicenter trial in 110 prepubertal GH-deficient children showed that daily subcutaneous sermorelin (30 mcg/kg) at bedtime increased mean height velocity from 4.1 to 8.0 cm/yr at 6 months, with good tolerability.
Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S (Geref International Study Group) — Journal of Clinical Endocrinology & Metabolism, Volume 81, Issue 3, Pages 1189-1196 1996
View source
BioDrugs (Springer)
Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
Comprehensive review of sermorelin pharmacology, diagnostic use, and pediatric efficacy data, with safety profile noting transient facial flushing and injection-site pain as the most common adverse events.
Prakash A, Goa KL — BioDrugs, Volume 12, Issue 2, Pages 139-157 1999
View source
Molecular Endocrinology (Oxford Academic)
Molecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone
Foundational paper that cloned and characterized the pituitary-specific GHRH receptor, establishing the G-protein coupled receptor mechanism by which sermorelin and other GHRH analogs stimulate endogenous growth hormone release.
Mayo KE — Molecular Endocrinology, Volume 6, Issue 10, Pages 1734-1744 1992
View source
Reviews in Endocrine and Metabolic Disorders (Springer)
Growth hormone-releasing hormone receptor (GHRH-R) and its signaling
Modern peer-reviewed review of GHRH receptor structure, signaling, splice variants, and therapeutic relevance of GHRH agonists like sermorelin across multiple disease contexts.
Halmos G, Szabo Z, Dobos N, Juhasz E, Schally AV — Reviews in Endocrine and Metabolic Disorders, Volume 26, Issue 3, Pages 343-352 2025
View source
Journal of Clinical Endocrinology & Metabolism (Oxford Academic)
Evidence for a limited growth hormone (GH)-releasing hormone (GHRH)-releasable quantity of GH: effects of 6-hour infusions of GHRH on GH secretion in normal man
Early adult human GHRH infusion study demonstrating that GHRH stimulates pulsatile GH release from the pituitary, with the magnitude of release limited by available pituitary GH stores.
Vance ML, Kaiser DL, Evans WS, Thorner MO, Furlanetto R, Rivier J, Vale W, Perisutti G, Frohman LA — Journal of Clinical Endocrinology & Metabolism, Volume 60, Issue 2, Pages 370-375 1985
View source
Journal of Clinical Endocrinology & Metabolism (Oxford Academic)
Lack of in vivo somatotroph desensitization or depletion after 14 days of continuous growth hormone (GH)-releasing hormone administration in normal men and a GH-deficient boy
Demonstrated that continuous 14-day GHRH administration in adults did not desensitize or deplete pituitary somatotrophs, supporting chronic GHRH-based therapy as a viable approach.
Vance ML, Kaiser DL, Martha PM Jr, Furlanetto R, Rivier J, Vale W, Thorner MO — Journal of Clinical Endocrinology & Metabolism, Volume 68, Issue 1, Pages 22-28 1989
View source
Journal of Clinical Endocrinology & Metabolism (Oxford Academic)
Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline
Endocrine Society clinical practice guideline covering diagnosis, treatment, and safety considerations for adult growth hormone deficiency, including GHRH-arginine testing methodology.
Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML — Journal of Clinical Endocrinology & Metabolism, Volume 96, Issue 6, Pages 1587-1609 2011
View source
Clinical Interventions in Aging (Dove Medical Press / PubMed Central)
Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Editorial discussing sermorelin as a physiologically gentler alternative to recombinant GH for age-related GH insufficiency, citing preserved negative feedback, episodic release, and lower risk of supraphysiologic IGF-1 levels.
Walker RF — Clinical Interventions in Aging, Volume 1, Issue 4, Pages 307-308 2006
View source
United States Pharmacopeia (USP)
USP General Chapter <797> Pharmaceutical Compounding - Sterile Preparations
The official USP standard governing sterile compounding (including injectable peptides like sermorelin) covering facility design, environmental monitoring, beyond-use dating, personnel training, and the new Category 1/2/3 CSP framework. Compounding pharmacies preparing sermorelin must comply with this chapter.
United States Pharmacopeial Convention — USP-NF 2023 Issue 1 (Official November 1, 2023) 2023
View source
U.S. Food and Drug Administration
Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act
Official FDA page describing the legal framework under which 503A pharmacies may compound from bulk drug substances. Sermorelin is permitted for 503A compounding via the 'component of a previously FDA-approved drug' pathway (former NDA 19-863 / 20-443, GEREF), since the original branded product was not withdrawn for safety or effectiveness.
U.S. Food and Drug Administration — FDA.gov Human Drug Compounding Program 2025
View source
U.S. Food and Drug Administration (Federal Register / FDA Guidance)
Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry; Availability
Finalized January 2025 FDA guidance defining the interim regulatory policy for 503A pharmacies compounding from bulk drug substances; relevant to the current legal pathway for compounded sermorelin in the United States.
U.S. Food and Drug Administration — Federal Register, January 7, 2025 2025
View source
Note on Regulatory Status (Editorial Disclosure)
Sermorelin Regulatory Status Disclosure
TRANSPARENCY NOTE: Branded sermorelin (GEREF) historically held FDA approval for pediatric GH-deficiency diagnosis and treatment but was discontinued by the manufacturer in 2008 (not for safety or efficacy reasons). Sermorelin is NOT currently FDA-approved for any indication in adults. It remains legally available in the U.S. only via 503A compounding pharmacies under valid prescription. This disclosure must accompany consumer-facing references for Nuvari's REWIND Protocol.
2026
View source
GEREF® is a registered trademark of its owner. Nuvari is not affiliated with or endorsed by the trademark owner.
